CCL

Összesen 3 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM078164
035-os BibID:(PMID)30953675 (WoS)000464978100009 (Scopus)85063866299
Első szerző:Márton Éva (biológus)
Cím:Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer / Éva Márton, János Lukács, András Penyige, Eszter Janka, Lídia Hegedüs, Beáta Soltész, Gábor Méhes, Róbert Póka, Bálint Nagy, Melinda Szilágyi
Dátum:2019
ISSN:0168-1656
Megjegyzések:Ovarian cancer is the fifth most common cause of cancer death among women that is mostly due to the difficulty of early diagnosis. Circulating miRNAs proved to be reliable biomarkers in various cancers. We screened 9 miRNAs, which are involved in epithelial-mesenchymal transition, in the plasma samples of patients with malignant (n=28) or non-malignant (n=12) ovarian tumors and disease-free healthy volunteers (n=60) by qRT-PCR. The expression levels of miR200a, miR200b, miR200c, miR141, miR429, miR203a, miR34b (p<0.001) and miR34a (p<0.01) were significantly higher in the malignant samples than in healthy controls. MiR203a, miR141 (p<0.01), miR200a and miR429 (p<0.05) levels were also higher in malignant compared to non-malignant samples. ROC-AUC was the highest in the case of miR200c: 0.861 (95%CI=0.776-0.947). Spearman's rank correlation analysis revealed positive correlation between the plasma levels of the studied miRNAs that was the highest between miR200b and miR200c (rs = 0.774; p<0.001). Target analysis also suggested tight interaction between these miRNAs in the regulation of cancer development. The agreement of diagnostic tests based on miRNA levels and the standard CA125 or HE4 was weak according to Cohen's kappa values. We conclude that miR200 family members, miR34b and miR203a might be promising complementary biomarkers in ovarian cancer.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
petefészekrák
miRNS
miR200
miR34
miR203
CA125
HE4
Megjelenés:Journal of Biotechnology. - 297 (2019), p. 58-65. -
További szerzők:Lukács János (1975-) (szülész-nőgyógyász, genetikus) Penyige András (1954-) (molekuláris genetikus) Janka Eszter Anna (1989-) (bőrgyógyász, népegészségügyi szakember) Hegedüs Lídia Soltész Beáta (1987-) (molekuláris biológus) Méhes Gábor (1966-) (patológus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM074290
Első szerző:Márton Éva (biológus)
Cím:Study the role of miR141 and miR429 in the diagnosis of epithelial ovarian cancer / Éva Márton, János Lukács, Réka Szabó, Beáta Soltész, Eszter Janka, Róbert Póka, Bálint Nagy, Melinda Szilágyi-Bónizs
Dátum:2018
Megjegyzések:Ovarian cancer is the most lethal form of gynecological malignancy that is mostly due to the difficulty of early diagnosis. Developing a fast, non-invasive diagnostic test would greatly facilitate the early detection and survival chances of ovarian cancer. Circulating miRNAs proved to be promising biomarkers in various cancers, including breast, prostate, pancreatic or colon cancer. However, only few publications focus on circulating miRNAs in ovarian cancer especially in European populations.Here we studied the expression levels of miR141 and miR429 in the plasma samples of healthy (n=17), and previously untreated epithelial ovarian carcinoma patients (n=17, FIGO stages III or IV) in a Hungarian cohort. The relative amount of miRNAs was detected by qRT-PCR.The expression levels of miR141 and miR429 proved to be higher in the malignant samples compared to the healthy donors (p<0.05). ROC-AUC proved to be good in the case of both miR141 (0.737, 95%CI=0.565-0.909) and miR429 (0.727, 95%CI=0.552-0.901). Sensitivity and negative predictive value were higher in the case of miR429(76.47% and 75%) than in the case of miR141 (64.71% and 68.42%). However, specificity and positive predictive value proved to be higher in the case of miR141 (76.47% and 73.33%) than in the case of miR429 (70.59% and 72.22%). Diagnostic accuracy was higher in the case of miR429 (73.53%) than in the case of miR141 (70.59%).We conclude that the miR200 family member miR141 and miR429 might be promising candidate biomarkers in the diagnosis of ovarian cancer. Further studies are needed to test our hypothesis.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
miRNA
Wilms tumor
FFPE
Megjelenés:Biomedical Papers. - 162 : Suppl. 1 (2018), p. S17. -
További szerzők:Lukács János (1975-) (szülész-nőgyógyász, genetikus) Szabó Réka Soltész Beáta (1987-) (molekuláris biológus) Janka Eszter Anna (1989-) (bőrgyógyász, népegészségügyi szakember) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM074285
Első szerző:Szilágyi Melinda (biológus)
Cím:MiR200a, miR200b and miR200c are promising candidate biomarkers in epithelial ovarian cancer / Melinda Szilágyi-Bónizs, Éva Márton, János Lukács, Beáta Soltész, Eszter Janka, András Penyige, Róbert Póka, Bálint Nagy
Dátum:2018
Megjegyzések:Ovarian cancer is the fifth most common form of cancer death among women. Developing a fast, reliable blood test would facilitate the early detection of ovarian cancer, which would also contribute to the improvement of survival chances. Screening circulating miRNAs proved to be reliable biomarkers in various cancers. MiRNAs are also dysregulated in ovarian cancer, however, only a few publications focus on their diagnostic role. We screened 6 miRNAs in the plasma samples of healthy (n=30), previously untreated epithelial ovarian carcinoma patients (n=21, FIGO stages III or IV) and patients with benign masses (n=14). The relative amount of miRNAs was detected by qRT-PCR.The expression levels of miR200a, miR200b and miR200c were elevated in the malignant samples compared to the healthy donors (p<0.001). The level of miR200a was also higher in malignant than benign samples (p<0.01). However, no significant difference was detected in the expression of miR205, miR483 and let7f. ROC-AUC was the highest in the case of miR200a (0.875, 95%CI=0.76-0.99) and it was still promising in the case of miR200b (0.85, 95%CI=0.72-0.98) and miR200c (0.83, 95%CI=0.70-0.97). Spearman's rank correlation was relatively high between the expression values of miR200b and miR200c (rs = 0.858; p<0.001) and these miRNAs shared several target genes involved in cancer development according to target prediction analysis. The agreement of diagnostic tests based on miR200s and CA125 or HE4 proved to be weak according to Cohen's kappa values.We conclude that miR200a, miR200b and miR200c might be promising complementary markers of CA125 and HE4 in ovarian cancer. Moreover miR200a is also a reliable biomarker in the differential diagnosis of benign tumors.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
ovarian cancer
cell-free mtDNA
miRNA
Megjelenés:Biomedical Papers. - 162 : Suppl. 1 (2018), p. S11. -
További szerzők:Márton Éva (1992-) (biológus) Lukács János (1975-) (szülész-nőgyógyász, genetikus) Soltész Beáta (1987-) (molekuláris biológus) Janka Eszter Anna (1989-) (bőrgyógyász, népegészségügyi szakember) Penyige András (1954-) (molekuláris genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1